[Thrombopoietin: current and future status].
Thrombopoietin (TPO), which is a major physiological regulator of platelet production, was cloned in 1994. It has already been shown that the administration of recombinant TPO increases platelet production and accelerates platelet recovery after cytoablative therapy in preclinical and clinical trials. In addition, recent results indicate that the effects of TPO on hematopoiesis are more widespread than initially anticipated. In this article, physiological activities of TPO and results of clinical trials are briefly reviewed, and possible clinical application and some problems in its clinical use are discussed.
Teramura
M
M
Department of Hematology, Tokyo Women's Medical University, Japan.
Mizoguchi
H
H
D000818:Animals; D001792:Blood Platelets / Q000166:cytology*; D016179:Granulocyte Colony-Stimulating Factor / Q000494:pharmacology; D006410:Hematopoiesis; D006801:Humans; D008533:Megakaryocytes / Q000166:cytology; D010976:Platelet Count; D011994:Recombinant Proteins / Q000494:pharmacology; D013926:Thrombopoietin / Q000494:pharmacology / Q000502:physiology
D011994:Recombinant Proteins; D016179:Granulocyte Colony-Stimulating Factor; D013926:Thrombopoietin